Shaping the Mitral Valve Market through Medicare

ARTICLE SUMMARY:

Transcatheter mitral valve device developers jostle for advantage in providing feedback to CMS as it reconsiders its coverage policy.

Comments that came into the US Medicare agency last month broadly support an expanded and more flexible coverage policy for transcatheter mitral valve (TMV) treatments. But there are subtle distinctions between, on the one hand, first-to-market-mover Abbott Laboratories Inc.’s input to CMS and feedback from companies that are in earlier stages of development, underscoring how Medicare policies can play into competitive dynamics.

This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.


Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to Market Pathways:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to Market Pathways
Subscribe to ELITE Strategist

Become an ELITE Strategist and unlock access to both MedTech Strategist and MTS Market Pathways.

Subscribe to Elite

Questions?

We're here to help! Please contact us at: